Common Constipation Drug Shows Unexpected Promise in Protecting Kidneys, New Study Finds

Chronic kidney disease (CKD) is a growing global health crisis that affects hundreds of millions of people worldwide. It stands as one of the leading causes of kidney failure, a condition that forces many patients to rely on dialysis just to stay alive. While current treatments can slow the damage to some extent, no approved medications exist that can directly restore lost kidney function. However, researchers at Tohoku University Graduate School of Medicine in Japan have uncovered a surprising possibility involving a drug already sitting on pharmacy shelves: lubiprostone, a medication long used to treat chronic constipation.

In a clinical trial, lubiprostone appeared to slow the decline of kidney function in patients with moderate CKD. This finding raises hopes for an entirely new approach to treating kidney disease — one that targets the gut rather than the kidneys themselves.

The Surprising Link Between Constipation and Kidney Health

The connection between constipation and kidney disease might not seem obvious at first. But for years, doctors have noticed that people with CKD often struggle with constipation. This observation led researchers to dig deeper.

“We noticed that constipation is a symptom that often accompanies CKD, and decided to investigate this link further,” explains Dr. Abe, the lead researcher. “Essentially, constipation disrupts the intestinal microbiota, which worsens kidney function. Working backwards, we hypothesized that we could improve kidney function by treating constipation.”

This idea builds on a growing field of research called the “gut-kidney axis.” This term describes the complex relationship between the bacteria living in your intestines and the health of your kidneys. When the gut microbiome — the community of trillions of bacteria in your digestive system — becomes unbalanced, it can trigger inflammation and allow harmful compounds to build up in the body. For people with CKD, this can accelerate kidney damage.

What the LUBI-CKD Trial Actually Found

Earlier research had hinted that improving gut health might help protect the kidneys, but solid evidence in humans remained limited. To explore this idea more thoroughly, researchers launched a multicenter Phase II clinical trial called the LUBI-CKD TRIAL. The study took place across nine medical institutions in Japan.

The trial enrolled 150 patients with moderate chronic kidney disease. Half of the participants received lubiprostone, while the other half received a placebo. This setup allowed scientists to compare how the treatment affected kidney function over time.

The results surprised even the research team. Patients who received either 8 µg or 16 µg doses of lubiprostone showed a slower decline in kidney function compared with those in the placebo group. Kidney performance was measured using estimated glomerular filtration rate (eGFR), one of the most widely used indicators of kidney health. Think of eGFR as a report card for your kidneys — higher numbers mean better function.

Researchers reported that the protective effect appeared dose dependent, meaning higher doses were linked to greater benefits. The 16 µg group showed particularly promising preservation of kidney function signals during the 24-week trial period.

How a Constipation Drug Might Protect the Kidneys

After seeing these results, scientists wanted to understand exactly how lubiprostone was helping the kidneys. Their analysis pointed to changes in the gut microbiome.

Lubiprostone increased the production of spermidine, a naturally occurring compound tied to healthier mitochondrial activity. Mitochondria are often described as the power plants of cells because they generate the energy cells need to function properly. When mitochondria work well, cells throughout the body — including kidney cells — can operate more efficiently and resist damage.

The researchers found that improved mitochondrial function may help shield kidney tissue from further harm. They also identified changes in bacterial pathways connected to polyamine production, adding more evidence that gut microbes may directly influence kidney health.

Interestingly, the treatment did not significantly reduce certain uremic toxins that scientists originally expected to change. Uremic toxins are waste products that build up in the blood when kidneys fail. Instead, the kidney benefits seemed tied more closely to microbiome remodeling and mitochondrial support. That finding could reshape how researchers think about treating CKD in the future.

Why This Matters for People Living With Kidney Disease

For the millions of people living with CKD, this research offers a glimmer of hope. Even modest slowing of kidney decline could potentially delay the need for dialysis and improve quality of life. Dialysis is a life-sustaining but demanding treatment that typically requires multiple sessions per week, often leaving patients exhausted and restricted in their daily activities.

The fact that lubiprostone is already an approved medication for chronic constipation is significant. Because the drug has already passed safety reviews and is available by prescription, it could potentially move into clinical use for kidney patients faster than developing a completely new drug from scratch. This could mean lower costs and faster access for patients who might benefit.

What Experts Say About the Gut-Kidney Connection

Many nephrologists (kidney specialists) have become increasingly interested in the gut-kidney axis in recent years. Dr. Holly Kramer, a nephrologist at Loyola University Chicago, notes that “the idea that modifying the gut microbiome could affect kidney disease progression is gaining traction, but we need larger studies to confirm these findings.”

Other experts caution that while the results are promising, they come from a Phase II trial, which is still an early stage of research. Larger Phase III trials are needed to confirm whether the benefits hold up in broader patient populations. Scientists are also searching for biomarkers that could predict which patients are most likely to respond to treatment.

Beyond Kidney Disease: Broader Implications

Researchers also believe the discovery may have implications beyond kidney disease. Because mitochondrial dysfunction is involved in many chronic illnesses — including heart disease, diabetes, and neurodegenerative disorders — scientists are exploring whether similar gut-targeted approaches could eventually help other conditions as well.

The idea that a simple, inexpensive drug could influence mitochondrial health through the gut microbiome opens up new possibilities for treating a wide range of diseases. It’s a reminder that sometimes the most important medical discoveries come from unexpected places.

Practical Takeaways for Readers

While this research is still in its early stages, there are steps you can take now to support both your gut and kidney health:

– Stay hydrated: Drinking enough water helps both digestion and kidney function.

• Eat a fiber-rich diet: Foods like fruits, vegetables, whole grains, and legumes feed healthy gut bacteria.
• Limit processed foods: High-sodium, high-sugar diets can harm both gut bacteria and kidneys.
• Manage underlying conditions: Control blood pressure, blood sugar, and cholesterol to protect your kidneys.
• Talk to your doctor: If you have CKD and struggle with constipation, ask whether treatments targeting gut health might be appropriate for you.

What’s Next for This Research

The research team at Tohoku University is now planning larger Phase III trials to confirm their findings. If those trials are successful, lubiprostone could become one of the first medications to directly target the gut-kidney axis for kidney protection.

For now, the findings have added momentum to a rapidly growing area of medicine focused on the connection between gut bacteria, cellular energy production, and chronic disease progression. For people living with CKD, even modest slowing of kidney decline could potentially delay dialysis and improve quality of life.

The study was published by researchers at Tohoku University Graduate School of Medicine and has drawn attention from the medical community because of its novel approach. As one researcher put it, “Sometimes the best discoveries come from looking at old drugs in new ways.”

While more research is still needed, this study represents an important step forward in understanding how something as simple as treating constipation might help protect one of the body’s most vital organs.

Source: ScienceDaily